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The binding of transcription factor ATF-1 to DNA contributes to
gene expression and regulation of cell growth. Antibody Mab41.4,
raised against ATF-1, and its derivatives Fab41.4 and scFv41.4 inhibit
speci®c DNA binding in vitro and induce apoptotic death of tumor
cells in vivo. Structural studies of Fab41.4 were performed to gain
insight into the mechanism of action of this potentially therapeutic
antibody. The optimal conditions for crystallization of Fab41.4 were
determined. Crystals were needle-like in appearance, displayed C2
space-group symmetry and diffracted to a resolution of 1.6 AÊ . The
unit-cell parameters were determined to be a = 186.64, b = 40.22,
c = 55.58 AÊ ,  =  = 90,  = 96.93. The data set was 97.7% complete.
Molecular replacement was performed, resulting in an R value of
44.6%.
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1. Introduction
Activating transcription factor-1 (ATF-1) is a
member of the large bZIP family of tran-
scription factors. The de®ning features of the
bZIP superfamily include a DNA-binding
region containing basic amino-acid residues
(b) and a dimerization domain containing
heptad repeats of leucine, the leucine zipper
(ZIP). ATF-1 binds as a homodimer to DNA,
with each monomer having a molecular weight
of 36 000 Da. As a member of the CREB/ATF
subfamily, ATF-1 binds to a cAMP response
element (CRE), with the consensus sequence
being an eight base-pair palindrome
50-TGACGTCA-30 (Lee & Masson, 1993).
ATF-1 binds with high af®nity to the CRE
sequence and with considerably lower af®nity
to DNA sequences that are similar, such as the
AP-1 site (TGAGTCA; Bosilevac et al., 1998).
The speci®c role of ATF-1 in normal cells is
unknown; however, a chimeric protein
resulting from chromosomal translocation of
the ATF-1 DNA-binding domain is associated
with the development of a speci®c type of
cancer termed clear-cell sarcoma (Travis &
Bridge, 1992). Further, ATF-1 is expressed at
signi®cantly lower levels in differentiated cells
compared with undifferentiated cells, but is
overexpressed in continuously proliferating
cells such as HeLa cells (Masson et al., 1993). A
recent study has suggested that ATF-1 is also a
survival factor for human melanoma cells (Jean
et al., 2000).
X-ray diffraction studies have been reported
for the prototypic bZIP yeast transcription
factor GCN4 bound to AP-1 (O'Shea et al.,
1991) and CRE DNA (Ellenberger et al., 1992;
Konig & Richmond, 1993). The DNA-binding
domain of GCN4 consists of basic residues,
with a conserved asparagine contacting the
cytosine and thymidine within one half-site of a
CRE and a conserved arginine binding to the
cytosine and guanine of the second CRE half-
site (Konig & Richmond, 1993). The -helix of
GCN4 resided in the major groove; however,
no electron-density assignment was possible
beyond the DNA-binding domain. ATF-1
interactions with CRE DNA are expected to
be similar to those of GCN4.
Mab41.4 (IgG1,) is one of a group of
ATF-1-speci®c antibodies that were obtained
through use of recombinant ATF-1 as an
immunogen (Orten et al., 1994). Mab41.4 was
found to inhibit ATF-1/DNA binding in vitro
(Gilchrist et al., 1995) and in cells (Bosilevac et
al., 1998). Recently, the expression of scFv41.4
in MeWo melanoma cells suppressed tumor
growth and induced apoptosis in vivo (Jean et
al., 2000). The Fab of Mab41.4 contains the VL,
CL, VH and CH1 regions, which incorporate the
antigen-binding portions. In addition, recom-
binant scFv has been cloned (Bosilevac et al.,
1998) and, when expressed in cells, retained the
inhibitory activity of the parent antibody
(Bosilevac et al., 1999). scFv41.4 contains the
VH and VL regions of Mab41.4, with a 15
amino-acid linker inserted between the heavy
and light variable regions. The epitope of
antibody 41.4 has been mapped and is repre-
sented by a 15 amino-acid sequence, Peptide C.
Since scFv41.4 retains the inhibitory activity in
vivo, a structural analysis of its interactions is
important for guiding future re®nements.
Information regarding its structure is expected
to aid in the development of Fab41.4 analogs
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that may have greater af®nity or speci®city
for further experimental studies and thera-
peutic applications.
2. Methods and materials
Mab41.4 was obtained from ascites ¯uid as
described by Orten et al. (1994). Fab41.4 was
obtained from Mab41.4 by papain digestion.
Protein A column separation was used to
purify the Fab41.4 from the Fc41.4 frag-
ments and undigested Mab41.4. The Fab41.4
elution buffer was 3 M NaCl/1.5 M glycine
pH 8.9 (Gilchrist et al., 1995). The Fab41.4
was dialyzed into PBS and separated by
SDS±PAGE to determine the purity of the
product.
The preliminary crystallization experi-
ments were carried out using the vapor-
diffusion method and various crystal screens.
Crystals were obtained with the Hampton
Crystal Screen I (Cudney et al., 1994). By
adjusting the percentage of PEG, higher
quality crystals were generated. Subsequent
®ne screening identi®ed the optimal crys-
tallization conditions to be 22% PEG 8000,
0.1 M sodium cacodylate pH 6.5, 0.2 M
magnesium acetate and 10% glycerol. A
drop consisted of 3 ml 10 mg mlÿ1 Fab41.4
mixed with 3 ml of the reservoir solution.
Data collection was carried out on station
BL7-1 at the Stanford Synchrotron Radia-
tion Laboratory (SSRL) using a 345 mm
MAR Research image plate and radiation of
wavelength 1.08 AÊ . The crystallization
buffer performed as a cryobuffer that
allowed the crystals to be cryocooled by
rapid transfer to a nitrogen-gas stream at
100 K.
The data were reduced and the unit-cell
parameters were deduced using the HKL
software (Otwinoski & Minor, 1997). The
structure of Fab41.4 was solved using mole-
cular replacement with the evolutionary
search algorithm of the EPMR program
(Kissinger et al., 1999). Fab44.1 (IgG1,;
PDB ®le 1mlc) was selected as an initial
model because it produced the best results
compared with the other Fabs that were
examined using EMPR. A homology search
using the variable-region sequence against
the antibody database at Scripps was
performed. The VL region and the VH
region were replaced with the most homo-
logous crystallized antibodies. The rigid-
body re®nement from CNS (Brunger et al.,
1998) was applied using four domains: VL,
CL, VH and CH1.
3. Results and discussion
Crystal formation occurred within one week
of setup at room temperature. Typically,
needle-like crystals with several branching
sites were observed. The microseeding
technique yielded the most useful crystals
for X-ray analysis. (Fitzgerald & Madsen,
1986). Setups used 1 ml of microseeds
derived from the branched needle crystals
added to the drop. Long needle-shaped
single crystals appeared with typical dimen-
sions of 1  0.5  0.2 mm. Data were
collected from crystals of Fab41.4 alone.
Data conformed to a space-group symmetry
of C2, with unit-cell parameters a = 186.64,
b = 40.23, c = 55.58 AÊ ,  =  = 90,  = 96.93.
The crystal diffracted to a resolution of
1.6 AÊ . Assuming the molecular weight of
Fab41.4 to be 50 kDa and one Fab41.4 per
asymmetric unit, the respective volume per
unit molecular weight (VM) was
2.17 AÊ 3 Daÿ1 (Matthews, 1968).
The data set from a crystal of Fab41.4 was
97.7% complete (Table 1). Molecular
replacement using the evolutionary search
algorithm of the EPMR program was carried
out. First, molecular replacement of the
variable region was performed with Fab44.1,
yielding a best correlation coef®cient of
23%, with a 5% decrease in the second best
result. The constant region then underwent
molecular replacement resulting in a corre-
lation coef®cient of 43% and an R value of
47.7%. Subsequently, a variable-region
homology search identi®ed two antibodies
with a higher sequence homology than
Fab44.1, including Fab58.2 and MOPC21.
The VL region was replaced with the coor-
dinates of Fab58.2 (PDB ®le 1f58) and the
VH region was replaced with MOPC21
(PDB ®le 1igl) (Fig. 1). Using CNS, a rigid-
body re®nement of the four domains VL, CL,
VH and CH1 yielded an R value of 44.6%
and an Rfree (containing 5% of the data) of
47.3%. Current efforts are focused on
determining the structure of the comple-
mentarity-determining regions of Fab41.4.
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